CISplatin NDC 0143-9504

NDC codes

FDA NDC Directory

Product NDC (as listed)0143-9504Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00143-9504Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0143-9504-01	00143950401	1 VIAL, MULTI-DOSE in 1 CARTON (0143-9504-01) / 50 mL in 1 VIAL, MULTI-DOSEMarketed from Nov 7, 2000

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): CISplatin
Generic name (nonproprietary): cisplatin
Active ingredients: Cisplatin — 1 mg/mL
Dosage form: Injection
Route: Intravenous
Labeler: Hikma Pharmaceuticals USA Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 075036
Marketing start: Nov 7, 2000
Listing expires: Dec 31, 2026
Other FDA classes: Platinum-containing Compounds (EXT)
Identifiers: Product ID 0143-9504_b463892e-6ca3-4c57-ae72-bdd3a7370a08SPL ID b463892e-6ca3-4c57-ae72-bdd3a7370a08SPL set ID 76aea034-6d58-4390-a164-36aa09c1f101RxCUI 309311UNII Q20Q21Q62J
Pharmacologic class: Platinum-based Drug

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N400143950401 followed by a unit qualifier and the quantity

Package 00143-9504-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Nov 19, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

INDICATIONS Cisplatin Injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin Injection and cyclophosphamide. Cisplatin Injection, as a single agent, is indicated as secondary th…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 075036

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 075036
Product	Strength	Form · route	Labeler	Product NDC
CISplatin	Cisplatin 1 mg/mL	InjectionIntravenous	Hikma Pharmaceuticals USA Inc.	0143-9505